• Profile
Close

Cisplatin vs cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data

Cancer Dec 01, 2018

Bauml JM, et al. - Researchers compared treatment approaches for the nonoperative management of patients with head and neck squamous cell carcinoma (HNSCC): radiation therapy (RT) plus cisplatin or cetuximab. They used the Veterans Health Affairs system and identified patients with stage III to IVb HNSCC who had been treated nonsurgically with RT and cisplatin or cetuximab from 2000 to 2016. By the drug used in the first treatment cycle (intent to treat), participants were analyzed. According to findings, an inferior overall survival (OS) was observed in cases non-operatively managed with RT plus cetuximab, compared with cisplatin. Based on the findings, cisplatin could be the most appropriate partner for RT in this setting.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay